Wesbanco Bank Inc. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,894 shares of the medical research company’s stock after selling 939 shares during the period. Wesbanco Bank Inc.’s holdings in Amgen were worth $13,982,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Oakworth Capital Inc. raised its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock valued at $111,000 after buying an additional 100 shares during the period. Integrated Wealth Management raised its stake in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock valued at $141,000 after buying an additional 3 shares during the period. Delta Asset Management LLC TN raised its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock valued at $155,000 after buying an additional 85 shares during the period. Capital Advisors Ltd. LLC raised its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock valued at $164,000 after buying an additional 6 shares during the period. Finally, Hanson & Doremus Investment Management raised its stake in shares of Amgen by 3.0% in the second quarter. Hanson & Doremus Investment Management now owns 1,191 shares of the medical research company’s stock valued at $181,000 after buying an additional 35 shares during the period. Institutional investors and hedge funds own 79.18% of the company’s stock.

Amgen Inc. (NASDAQ:AMGN) opened at 172.96 on Friday. The firm has a 50-day moving average price of $171.85 and a 200-day moving average price of $158.72. Amgen Inc. has a 52 week low of $130.09 and a 52 week high of $176.64. The stock has a market cap of $129.44 billion, a P/E ratio of 17.70 and a beta of 0.87.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $2.57 EPS. On average, equities research analysts predict that Amgen Inc. will post $11.36 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were given a $1.00 dividend. The ex-dividend date was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a yield of 2.31%. Amgen’s payout ratio is 40.90%.

AMGN has been the subject of several research analyst reports. Goldman Sachs Group Inc. restated a “buy” rating on shares of Amgen in a report on Wednesday, June 29th. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $166.00 price objective for the company in a report on Wednesday, June 29th. Vetr upgraded Amgen from a “hold” rating to a “buy” rating and set a $159.50 price objective for the company in a report on Monday, June 13th. BMO Capital Markets restated a “buy” rating and issued a $186.00 price objective on shares of Amgen in a report on Tuesday, July 12th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $187.00 target price on shares of Amgen in a research report on Wednesday, July 13th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $184.87.

In other news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.20% of the stock is owned by company insiders.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.